The Thoracic Society of Australia and New Zealand
The Thoracic Society of Australia and New Zealand (TSANZ) is the only health peak body representing a range of professions (medical specialists, scientists, researchers, academics, nurses, physiotherapists, students and others) across various disciplines within the respiratory/sleep medicine field in Australia and New Zealand. The TSANZ is a Health Promotion Charity. TSANZ is committed to serving the professional needs of its members by improving knowledge and understanding of lung disease, with the ultimate goals being to prevent respiratory illness through research and health promotion and to improve health care for people with respiratory illness.
Do not delay immunisation/s based on presence of mild respiratory symptoms in the absence of fever.
Major guidelines on immunisation/vaccination do not cite the presence of minor or moderate acute illness (including mild respiratory symptoms), whether with or without fever, as a contraindication for immunisation. Australian immunisation guidelines explicitly state that ‘mild illness without fever’ is not a contraindication while US guidelines state that mild acute illness ‘with or without fever’ are ‘commonly misperceived’ as contraindications. Failure to immunise children with minor illnesses can reduce the effectiveness of immunisation campaigns. Given these considerations we adopt the conservative formulation that at least in the absence of fever, immunisation should not be delayed due to the mere presence of mild respiratory symptoms.
- Australian Immunisation Handbook 10th edition 2015.
- Canadian Immunization Guide 2016.
- Centres for Disease Control and Prevention General Best Practice Guidelines for Immunization: Best Practices Guidance of the Advisory Committee on Immunization Practices (ACIP).
In 2018 The Royal Australasian College of Physicians worked with a Lead Fellow nominated by The Thoracic Society of Australia and New Zealand (TSANZ) to review evidence for 12 paediatric thoracic recommendations on low-value care in paediatric thoracic medicine. These recommendations were the subject of email discussions and deliberation by members of the Paediatric Special Interest Group (SIG) of the TSANZ. They were further discussed at a workshop held at a meeting of the Asia Pacific Society of Respirology in 2017, which included TSANZ members. Based on the feedback provided at this workshop and through email discussions with members of the SIG, four were removed and two of the original 12 were considered for inclusion in the final recommendations with overwhelming support. Members of the Paediatric SIG were then invited to choose three out of the remaining six through an email based poll. This served as the basis for final recommendations, which were further refined and developed through successive drafts based on the input of the Lead Fellow, the results of consultation with other specialty groups and the views of the TSANZ Board.
In 2020 TSANZ worked with RACP’s Policy & Advocacy team as part of the Evolve program to develop a long list of low-value practices and interventions that pertain to the specialty. Through extensive research and redrafting under the guidance of the TSANZ Central Office and members of the TSANZ Board, the list was condensed to the top-5 recommendations for reducing low-value practices in adult thoracic medicine. After several rounds of internal consultations and revisions, the list of recommendations was subject to an extensive review process that involved key College societies with an interest in or professional engagement with thoracic medicine.
Per usual processes, the recommendations were then consulted with other medical colleges through Choosing Wisely Australia. Feedback received in the consultations led to further work and refinements by Policy & Advocacy and TSANZ, which approved these top-5 recommendations.
- 1 Do not prescribe combination therapy (inhaled corticosteroids with long-acting beta2 agonist) as initial therapy in mild to moderate asthma before a trial of inhaled corticosteroids alone.
- 2 Do not prescribe antibiotics for exacerbation of asthma.
- 3 Do not use oral beta2 agonists as bronchodilators in asthma, wheeze or bronchiolitis.
- 4 For children with bronchiolitis without other co-morbidities, do not delay discharge from an inpatient admission based on oxygen saturations alone if saturations are ≥90%.
- 5 Do not delay immunisation/s based on presence of mild respiratory symptoms in the absence of fever.
- 6 Do not perform a D-Dimer in patients at high risk of pulmonary embolism
- 7 Do not use long term systemic corticosteroids for management of chronic obstructive pulmonary disease (COPD)
- 8 Do not initiate maintenance inhalers in minimally symptomatic COPD patients with a low risk of exacerbation
- 9 Do not routinely follow-up solid pulmonary nodules smaller than 6 mm detected in low- risk patients
- 10 Do not perform a serum ACE for the diagnosis or monitoring of sarcoidosis